Drugs / HPV Specific T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02379520 | Sep 2015 → Jan 2026 | anal carcinoma, cervical carcinoma, oropharyngeal carcinoma, penile carcinoma +1 | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HPV Specific T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02379520 ↗ |
| Modality | Cell therapy | “special immune system cells called HPVST cells, a new experimental treatment” NCT02379520 ↗ |
| Route | Intravenous | “HPVSTs will be given by IV injection over 1-10 minutes through a peripheral or a central line on day 0” NCT02379520 ↗ |